The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate the effects of memantine in ALS patients using functional outcome measures.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Collaborator: ALS Association
• Treatments: Memantine

Criteria

Inclusion Criteria:

• El Escorial Classification of laboratory supported probable, probable,or definite ALS

• Age 18 - 80 years,

• ALS symptoms for no more than 3 years,

• FVC greater than or equal to 60% predicted,

• Riluzole naïve or have been on a stable dose of Riluzole for at least 2 months,

• Patients must have the ability to attend monthly study visits in Edmonton or Calgary, Alberta

Exclusion Criteria:

• Presence of significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and psychiatric illness

• Female patients who are breastfeeding

• Use of concurrent investigational drugs,

• Patient unlikely to comply with study requirements

• Poor adherence to study protocol during run-in phase